Posted 10 April 2019
The Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA) have jointly sent warning letters to Nutra Pure LLC, PotNetwork Holdings, Inc., and Advanced Spine and Pain, LLC (d/b/a Relievus) because they believe the companies are illegally marketing products containing cannabidiol (CBD) to treat a variety of serious diseases and conditions.
[FTC joins FDA in sending warning letters to companies advertising and selling products containing cannabidiol (CBD) claiming to treat Alzheimer’s, cancer, and other diseases. FTC Press Release. April 2, 2019]
CBD is a chemical compound found in marijuana and hemp that does not produce a high. In 2018, the FDA approved a cannabidiol preparation (brand name Epidiolex) to treat two rare, severe forms of epilepsy. But since 2015, the FDA has ordered many companies to stop making unapproved claims.
The market for unapproved CBD products is nevertheless burgeoning, as consumer protection is lacking. The FDA and others have found that some CBD products have not contained dosages claimed by marketers. Dangerous chemicals have been found in popular CBD vaping liquids.
Although there is great interest in potential medical uses for CBD, the evidence for its safety and effectiveness falls far short of the marketing hype for available products.
Consumer Health Digest #19-14, April 6, 2019